Nymox Pharmaceutical Corporation
News and Blogs
Total : 2 View more »
Nymox Pharmaceutical to Present at the Growth and Value Investor Conference (Business Wire)
biz.yahoo.com | Feb 14, 2008
Nymox Pharmaceutical to Present at the Growth and Value Investor Conference. - HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX - News) announced today that the Company will present at the 2008 Growth & Value Investor Conference to be held in at the Westin
Nymox Pharmaceutical Corporation News - The New York Times
Log In Register Now Home Page My Times Today's Paper Video Most Popular Times Topics Business All NYT New York Times Business World U.S. N.Y. / Region Business Media & Advertising World Business Small Business Your Money DealBook Markets Research Mutual Funds My Portfolio Alerts Technology Science
http://topics.nytimes.com/top/news/business/companies/nymox-pharmaceutical-corporation/index.html
Web Sites
Total : 88 View more »
Nymox Reports 2007 Financial Results
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX - News) announced today its financial results for the year ended December 31, 2007. Nymox reported a net loss of $5,290,431, or $0.
NYMOX: New Measures for Prevention ... Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's
MAYWOOD, N.J. (November 22, 2002) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) receives favorable coverage in a new Standard & Poor's Stock Report. The new report on Nymox rates the stock as "bullish" on technical evaluation.
Biospace.com
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Dec. 6, 2005--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that Cohen Independent Research Group has issued a "Buy" recommendation in newly written research coverage on the Company. The report is available at www.cohenresearch.
The Sonnenreich Corporation | Company :: Clients :: Some of our Clients
Developed core technology and provided management expertise for Pharmatrak service division. Involved over 3 years of development and execution management.
News from Zibb.com
Total : 6 View more »
Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
Nov 15, 2008 (Wall Street Horizon via COMTEX) --
Nymox Pharmaceutical Corporation (NYMX)
Expected next earnings release: Announcement date: 3/12/2009 - During Market Earnings Quarter: Q4 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: Nymox Pharmaceutical Corp. (NYMX)
Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
Oct 04, 2008 (Wall Street Horizon via COMTEX) --
Nymox Pharmaceutical Corporation (NYMX)
Expected next earnings release: Announcement date: 11/13/2008 - During Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: Nymox Pharmaceutical Corp. (NYMX)
Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
Nov 13, 2008 (Wall Street Horizon via COMTEX) --
Nymox Pharmaceutical Corporation (NYMX)
Expected next earnings release: Announcement date: 11/14/2008 - During Market Earnings Quarter: Q3 Announcement Status: Unconfirmed
Tags: corporate earnings market pharmaceuticals
Companies: Nymox Pharmaceutical Corp. (NYMX)
Nymox Reports Third Quarter 2008 Financial Results - Zibb.com
HASBROUCK HEIGHTS, N.J., Nov 14, 2008 (BUSINESS WIRE) --
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2008. Nymox reported a net loss of $1,350,536, or $0.05 per share for the quarter ending September 30, 2008, compared to $1,386,084, or $0.05 per share for same period in 2007. Product sales amounted to $82,171 for the third quarter of 2008, compared to $62,132 for the same period in 2007. The weighted average number of common shares for the quarter ended September 30, 2008 was 29,815,670, compared to 29,646,249 for the same period in 2007.
Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is in late stage development of NX-1207, a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure, and AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE: Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation Roy Wolvin, 1-800-93NYMOX www.nymox.com
Tags: alzheimers biotechnology disease drugs email financial results infection nasdaq patent pharmaceuticals pipeline population products securities tobacco
Companies: Nymox Pharmaceutical Corp. (NYMX)
News from Zibb.com
- Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
- Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
- Nymox Pharmaceutical Corporation (NYMX) Corporate Event Announcement Notice - Zibb.com
- Nymox Reports Third Quarter 2008 Financial Results - Zibb.com
Explore Related Products
- Drug Development
- Asset Management
- Testers
- Diagnostic Products
- Clinical Research
- Drug Screening
- Internet Portals
- Marketing Services
- Safety Studies
- Test Kits
- Antibacterial Agents
- Healthcare Devices
Explore in Related Industries
- Nymox Pharmaceutical Corporation in:
- Chemicals, Plastics & Rubber (85)
- Finance & Tax (3)
- Healthcare & Medicine (3)
- General Business (2)
- Electronics (2)
Explore Related Topics
- Diseases & Conditions
- Stocks & Stock Market
- Chemical Industry Research & Development
- Accounting & Finance
- Health
- Product Testing
- Cancer
- Chemical Market Intellectual Property & Patents
- Financial Reporting
- Jobs & Careers
- Search Engine Marketing
- Search Engines
